US 12,291,539 B2
KRAS G12C inhibitors
Snahel Patel, Foster City, CA (US); Philip A. Gerken, San Francisco, CA (US); and Monika Jane Williams, Woodside, CA (US)
Assigned to Frontier Medicines Corporation, South San Francisco, CA (US)
Filed by Frontier Medicines Corporation, South San Francisco, CA (US)
Filed on Jul. 24, 2024, as Appl. No. 18/783,394.
Application 18/783,394 is a continuation of application No. 18/707,499, previously published as PCT/US2022/079324, filed on Nov. 4, 2022.
Claims priority of provisional application 63/403,565, filed on Sep. 2, 2022.
Claims priority of provisional application 63/356,906, filed on Jun. 29, 2022.
Claims priority of provisional application 63/276,478, filed on Nov. 5, 2021.
Prior Publication US 2025/0019387 A1, Jan. 16, 2025
Int. Cl. C07D 519/00 (2006.01); C07D 471/04 (2006.01)
CPC C07D 519/00 (2013.01) [C07D 471/04 (2013.01)] 29 Claims
 
1. A compound of Formula II:

OG Complex Work Unit Chemistry
or a salt thereof, or an isotopologue thereof, or a salt of an isotopologue thereof;
wherein:
Rx is hydrogen;
R1 is

OG Complex Work Unit Chemistry
R2 is R2c;
R3 is fluoro;
R4 is fluoro, chloro, methyl, ethyl, or ethynyl;
R2c is —NR15R16;
R15 is methyl;
R16

OG Complex Work Unit Chemistry
R18 is hydrogen, —(CH2)z—NR22R23, —(CH2)u—R34, or R35;
R19 is hydrogen;
R20 is hydrogen;
R22 and R23 are each methyl;
z is 1;
R34 is azetidine substituted with 1 instance of methyl, pyrrolidine substituted with 1 instance of methoxy or fluoro, 2-oxa-5-azabicyclo[2.2.1]heptane, 3-oxa-8-azabicyclo[3.2.1]octane, or 3-oxa-6-azabicyclo[3.1.1]heptane;
u is 0 or 1; and
R35 is

OG Complex Work Unit Chemistry